多发性骨髓瘤患者对化疗及串联自体移植的反应与GSTP1和TYMS基因多态性
Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms.
作者信息
Maggini Valentina, Buda Gabriele, Galimberti Sara, Conidi Elena, Giuliani Nicola, Morabito Fortunato, Genestreti Giovenzio, Iacopino Pasquale, Rizzoli Vittorio, Barale Roberto, Petrini Mario, Rossi Anna Maria
机构信息
Department of Biology, Pisa University, Pisa, Italy.
出版信息
Leuk Res. 2008 Jan;32(1):49-53. doi: 10.1016/j.leukres.2007.03.029. Epub 2007 May 23.
This study examines the response to dexamethasone-doxorubicin-vincristine (DAV) therapy, followed by conditioning regimen and autologous stem cells transplantation (ASCT) in patients with multiple myeloma in relation with the presence of polymorphisms in genes involved in drug metabolism (GSTP1) and DNA synthesis (TYMS). GSTP1 G313G genotype (OR=5.49; 95% CI, 1.3-22.5, p=0.02) and TYMS A227A genotype (OR=3.41; 95% CI, 1.3-8.9, p=0.01) resulted significantly associated with a poor response following chemotherapy and the risk increased for the combined genotype (OR=13.54; 95% CI, 2.0-91.3, p=0.01). TYMS T157T genotype was significantly associated with a poor response after ASCT (OR=4.60; 95% CI, 1.2-16.9, p=0.02). Pre-therapeutic individual determination of the GSTP1 and TYMS polymorphisms could help in choosing the most appropriate protocol.
本研究探讨了多发性骨髓瘤患者接受地塞米松-阿霉素-长春新碱（DAV）治疗，随后进行预处理方案和自体干细胞移植（ASCT）时，其药物代谢相关基因（GSTP1）和DNA合成相关基因（TYMS）多态性的存在情况与治疗反应的关系。GSTP1 G313G基因型（优势比=5.49；95%置信区间，1.3-22.5，p=0.02）和TYMS A227A基因型（优势比=3.41；95%置信区间，1.3-8.9，p=0.01）与化疗后反应不佳显著相关，联合基因型的风险增加（优势比=13.54；95%置信区间，2.0-91.3，p=0.01）。TYMS T157T基因型与ASCT后反应不佳显著相关（优势比=4.60；95%置信区间，1.2-16.9，p=0.02）。治疗前对GSTP1和TYMS多态性进行个体测定有助于选择最合适的治疗方案。
Zotero 插件